BridgeBio Pharma, Inc. (BBIO)

Import this data to Google Sheets with:

=jivedata("BBIO","financials")

Full statements spill as a table. For one cell: =jivedata("BBIO","Revenue") or =jivedata("BBIO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

BridgeBio Pharma, Inc.

BBIO • CIK 0001743881

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-607,370	$-592,973	$-523,411	$-497,796
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	$-542,194	$-732,503	$-703,683
Income Tax Expense (Benefit)	—	$1,153	$435	$-1,665
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-653,251	$-543,347	$-732,938	$-702,018
Net Income (Loss) Attributable to Noncontrolling Interest	$-10,049	$-7,585	$-8,007	$-10,153
Net Income (Loss) Available to Common Stockholders, Basic	$-643,202	$-535,762	$-724,931	$-691,865
Weighted Average Number of Shares Outstanding, Basic	162,791,511	186,075,873	191,527,482	196,485,863
Revenue from Contract with Customer, Excluding Assessed Tax	$9,303	$221,902	$502,076	$713,069
Research and Development Expense	$455,711	$506,461	$451,953	$505,375
Selling, General and Administrative Expense	$150,590	$288,931	$531,225	$645,863
Restructuring, Settlement and Impairment Provisions	$7,926	$15,605	$21,347	$19,972
Costs and Expenses	$616,673	$814,875	$1,025,487	$1,210,865
Investment Income, Interest	$18,038	$17,249	$19,854	$23,476
InterestExpenseNonoperating	—	$99,290	$53,103	$-455
Deconsolidation, Gain (Loss), Amount	—	$178,321	$0	$0
Gain (Loss) on Extinguishment of Debt	$0	$-26,590	$-21,155	$0
Income (Loss) from Equity Method Investments	—	$-31,183	$-72,608	$-61,581
Other Nonoperating Income (Expense)	$17,370	$12,272	$43,058	$38,119
Nonoperating Income (Expense)	$-45,881	$50,779	$-209,092	$-205,887
Cost of Revenue	$2,446	$3,878	$20,962	$39,655

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Equity Method Investments	—	—	$79,972	$55,095
Property, Plant and Equipment, Net	$11,816	$7,011	$5,366	$5,226
Operating Lease, Right-of-Use Asset	$8,027	$5,767	$8,149	$17,079
Intangible Assets, Net (Excluding Goodwill)	$26,319	$23,926	$28,077	$26,641
Other Assets, Noncurrent	$22,625	$18,195	$16,712	$20,120
Assets	$546,380	$919,338	$936,025	$1,217,299
Long-term Debt, Excluding Current Maturities	$446,445	$437,337	—	$0
Operating Lease, Liability, Noncurrent	$8,981	$4,696	$3,811	$14,973
Contract with Customer, Liability, Noncurrent	—	—	$13,080	$10,424
Other Liabilities, Noncurrent	$9,361	$286	$244	$240
Liabilities	$1,888,915	$2,376,950	$3,012,606	$3,723,192
Cash and Cash Equivalents, at Carrying Value	$375,935	$681,101	$570,119	$677,911
Debt Securities, Available-for-sale, Current	—	—	$17,363	$42,249
Accounts Receivable, after Allowance for Credit Loss, Current	—	$4,722	$139,444	$254,484
Inventory, Net	—	—	$26,753	$52,842
Prepaid Expense and Other Assets, Current	$24,305	$34,743	$44,070	$65,652
Assets, Current	$477,593	$720,692	$797,749	$1,093,138
Accounts Payable, Current	$10,655	$9,618	$36,228	$27,202
Employee-related Liabilities, Current	$57,370	$58,329	$76,703	$49,976
Operating Lease, Liability, Current	$4,128	$4,506	$6,192	$3,315
Contract with Customer, Liability, Current	—	—	$7,190	$5,546
Other Liabilities, Current	—	—	$120,222	$192,186
Liabilities, Current	$143,844	$154,400	$287,971	$890,648
Preferred Stock, Value, Issued	—	—	$0	$0
Common Stock, Value, Issued	$181	$196	$202	$206
Treasury Stock, Common, Value	—	—	$323,276	$533,279
Additional Paid in Capital	—	—	$2,057,646	$2,155,318
Accumulated Other Comprehensive Income (Loss), Net of Tax	$31	$8	$12	$-7
Retained Earnings (Accumulated Deficit)	$-2,560,501	$-3,096,263	$-3,821,194	$-4,137,453
Stockholders' Equity Attributable to Parent	$-1,354,257	$-1,467,904	$-2,086,610	$-2,515,215
Stockholders' Equity Attributable to Noncontrolling Interest	$11,244	$10,150	$10,599	$10,340
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$-1,343,013	$-1,457,754	$-2,076,011	$-2,504,875
Preferred Stock, Shares Authorized	25,000,000	25,000,000	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000	500,000,000
Common Stock, Shares, Issued	181,274,712	196,236,234	202,369,129	205,867,350
Common Stock, Shares, Outstanding	175,082,951	190,044,473	194,771,957	195,284,352
Treasury Stock, Common, Shares	6,191,761	6,191,761	7,597,172	10,582,998
Inventory, Raw Materials, Gross	—	—	$14,997	$27,853
Inventory, Work in Process, Gross	—	—	$6,104	$16,700
Inventory, Finished Goods, Gross	—	—	$6,509	$11,119
Inventory Valuation Reserves	—	—	$857	$2,830

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-22,152	$288,512	$-111,104	$-71,064
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$394,732	$683,244	$572,140	$911,416
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-653,251	$-543,347	$-732,938	$-702,018
Net Cash Provided by (Used in) Operating Activities	$-527,720	$-520,726	$-445,910	$-434,374
Payments to Acquire Debt Securities, Available-for-sale	—	—	$28,197	$84,226
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	—	—	$11,000	$50,600
PaymentsToAcquireEquitySecuritiesFvNi	$107,538	$20,271	$0	$0
ProceedsFromSaleOfEquitySecuritiesFvNi	$110,556	$63,229	$0	$0
Proceeds from Equity Method Investment, Distribution, Return of Capital	—	$25,682	$2,302	$2,302
Payments to Acquire Intangible Assets	$0	$7,975	$8,495	$2,400
Payments to Acquire Property, Plant, and Equipment	$1,306	$933	$1,097	$1,015
Cash Divested from Deconsolidation	—	—	$0	$0
Net Cash Provided by (Used in) Investing Activities	$54,033	$60,781	$-24,487	$-34,739
Proceeds from Convertible Debt	$0	—	—	$0
Payments of Debt Issuance Costs	$0	$15,986	—	$15,986
Payments for Repurchase of Common Stock	$0	—	$48,276	$210,003
Repayments of Lines of Credit	—	—	$459,000	$0
Proceeds from Issuance of Common Stock	$144,049	$314,741	$0	$0
Proceeds from Stock Plans	$3,398	$4,502	$6,414	$8,643
Proceeds from Stock Options Exercised	$6,008	$3,656	$27,735	$45,867
Proceeds from (Payments to) Noncontrolling Interests	—	—	$2,150	$600
Payment, Tax Withholding, Share-based Payment Arrangement	$6,880	$7,526	$14,226	$18,796
Net Cash Provided by (Used in) Financing Activities	$451,535	$748,457	$359,293	$398,049
Interest Paid, Excluding Capitalized Interest, Operating Activities	$61,108	$91,342	$43,670	$40,715
Income Taxes Paid	—	—	$1,198	$1,198
Capital Expenditures Incurred but Not yet Paid	$100	$279	$43	$-282
Cash and Cash Equivalents, at Carrying Value	$375,935	$681,101	$570,119	$909,411
Restricted Cash, Current	$16,653	$126	$550	$974
Restricted Cash, Noncurrent	$2,144	$2,017	$1,471	$1,031
Share-based Payment Arrangement, Noncash Expense	$108,710	$95,800	$133,024	$147,215
Gain (Loss) on Extinguishment of Debt	$0	$-26,590	$-21,155	$0
Amortization of Debt Issuance Costs and Discounts	$3,662	$3,761	$5,967	$7,164
Depreciation, Depletion and Amortization	$6,494	$6,075	$5,434	$5,072
Operating Lease, Right-of-Use Asset, Amortization Expense	—	—	$4,902	$5,766
Income (Loss) from Equity Method Investments	—	$-31,183	$-72,608	$-61,581
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	—	—	$19,652	$19,883
Equity Securities, FV-NI, Gain (Loss)	$18,314	$8,136	$0	$0
Other Noncash Income (Expense)	$-181	$2,756	$1,651	$-5,315
Increase (Decrease) in Accounts Receivable	—	$2,971	$134,722	$177,616
Increase (Decrease) in Inventories	—	—	$25,307	$36,891
Increase (Decrease) in Prepaid Expense and Other Assets	$2,702	$13,918	$8,777	$6,259
Increase (Decrease) in Other Operating Assets	$1,546	$-1,542	$-1,113	$1,996
Increase (Decrease) in Accounts Payable	$2,780	$1,512	$26,609	$1,067
Increase (Decrease) in Employee Related Liabilities	$7,802	$16,986	$23,022	$12,904
IncreaseDecreaseInOperatingLeaseLiability	$-4,829	$-5,902	$-6,547	$-7,104
Increase (Decrease) in Deferred Revenue	$-5,438	$21,875	$-11,428	$-9,237
Increase (Decrease) in Other Operating Liabilities	—	—	$77,810	$103,606

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("BBIO","financials")

Full statements spill as a table. For one cell: =jivedata("BBIO","Revenue") or =jivedata("BBIO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.